[1]陆克义,李险峰,段炼,等.Graves’病患者131Ⅰ治疗后对其周围人群辐射当量剂量的评估[J].国际放射医学核医学杂志,2006,30(6):347-349,352.
　LU Ke-yi,LI Xian-feng,DUAN Lian,et al.Evaluation of the dose equivalent from patients with Graves’ disease after 131Ⅰ therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):347-349,352.
点击复制

Graves’病患者131Ⅰ治疗后对其周围人群辐射当量剂量的评估(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
30
期数:
2006年第6期
页码:
347-349,352
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Evaluation of the dose equivalent from patients with Graves’ disease after 131Ⅰ therapy
作者:
陆克义1;  李险峰1;  段炼1;  张承刚1;  刘建中1;  曹润林2;  李思进1
1. 030001 太原, 山西医科大学第一医院核医学科;
2. 030003 太原, 太原钢铁(集团)有限公司总医院核医学科
Author(s):
LU Ke-yi1;  LI Xian-feng1;  DUAN Lian1;  ZHANG Cheng-gang1;  LIU Jian-zhong1;  CAO Run-lin2;  Li Si-jin1
1. Department of Nuclear Medicine, the First Hospital of Shanxi Medical University, Taiyuan 030001, China;
2. Department of Nuclear Medicine, the Chief Hospital of Taiyuan Steel Company, Taiyuan 030003, China
关键词:
碘放射性同位素; 放射疗法; 格雷夫斯病; 辐射剂量
Keywords:
Iodine radioisotopes; Radiotherapy; Graves’ disease; Radiation dosage
分类号:
R144.1
摘要:
目的 通过对用131Ⅰ治疗Graves’病后患者当量剂量值的计算,评价该患者对周围人群可能产生的辐射危害。方法 对131Ⅰ治疗的Graves’病患者进行实际测量和随访,完成每日的实际测量及接触周围人群情况,获取甲状腺摄131Ⅰ百分数、131Ⅰ投入的总剂量、周围人群与患者限制情况、实际测量当量剂量率及周围人群确切接触时间等参数,将实际测量累积法测得的当量剂量值与公式法计算结果比较。结果 经131Ⅰ治疗后,所有Graves’病患者对周围人群的当量剂量值均在正常范围内,实际测量累积法较单一公式法高(t=3.953,P<0.001);周围成人与患者接触时间≤6d时,实际测量累积法较高(t=3.894,P<0.001);而对与患者接触时间>6d的周围成人和限制条件下的周围儿童,实际测量累积法与公式法无明显差异(t1=0.910,t2=1.705,P>0.05)。结论 131Ⅰ治疗Graves’病患者对周围人群是安全的,实际测量累积法计算的当量剂量值更实际。
Abstract:
Objective By calculating the dose equivalent to patients with Graves’ disease by 131Ⅰ therapy, to evaluate the radiation safety of the individuals around the patients. Methods All patients had heed achieved the practical measure and follow-up, there attained the percentage of thyroid 131Ⅰ uptake, the 131Ⅰ dose, the duration of constrained social activity, and practical measure the effective dose equivalent rate and contact exact time with others, and compared the exposure dose to the individuals with the simplistic formula and practical measure accumulating dose calculating methods. Results For all patients with Graves’ disease, the exposure doses to the individuals were not likely to exceed normal, Practical measure accumulating doses is higher than the simplistic formula calculating ones (t=3.953, P<0.001). When the adults’ contact restricted time with the patients not exceed 6 days, practical measure accumulating calculating doses is higher (t=3.894, P<0.001), but exceed 6 days and enfant (commonly restricted), there were no difference between the simplistic formula calculating doses and practical measure accumulating calculating ones (t1=0.910, t2=1.705, respectively P>0.05). Conclusions All patients with 131Ⅰ therapy were safety to the individuals surrounding to the patients, practical measure accumulating doses is better and more practical.

参考文献/References:

1 Singer PA, Crooper DS, Levy EC, et al. Treatment guidelines for patients with hyperthyroidism and hypothyoidism. JAMA, 1995,273(10):808-812.
2 李险峰,晋建华,张东红,等.甲状腺疾病131I治疗的辐射危害评价.中华核医学杂志,2004,24(3):191.
3 GB18871-2002.电离辐射防护与辐射源安全基本标准.
4 Coover LR, Silberstein EB, Kuhn PJ, et al. Therapeutic 131Ⅰ in outpatients:a simplified method conforming to the code of federal regulations, title 10, part 35.75. J Nucl Med, 2000, 41(11):1868-1875.
5 US Nuclear Regulatory Commission. 10 CFR Part 35.75:Release of individuals containing unsealed byproduct material or implants containing byproduct material. Washington DC:US Government Printing Office, 2000.
6 Friedman MI, Ghesani M. Interactive software automates personalized radiation safety plans for Na131Ⅰ therapy. Health Phys,2002, 83(11Suppl):S71-S84.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
　Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[3]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
　Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
　Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]赵德云,李百龙.植物提取物防治放射性肺损伤的现状与展望[J].国际放射医学核医学杂志,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
　Zhao Deyun,Li Bailong.Protective and therapeutic effects of plant extracts on radiation-induced lung injury:present status and future prospects[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
[6]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[7]邓大平,卢峰,孙洪强,等.颅脑肿瘤放射治疗时射野外器官吸收剂量体模法测量与分析[J].国际放射医学核医学杂志,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
　Deng Daping,Lu Feng,Sun Hongqiang,et al.Test and analysis of out-of-field organ dose in intracranial tumor radiotherapy using phantom[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
[8]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[9]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
　zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[10]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
　Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[11]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[12]汤建林,李玉莹,高柳艳,等.131I治疗Graves病规范化建设体会[J].国际放射医学核医学杂志,2011,35(3):179.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]
　TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.Standardization of 131I therapy for Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):179.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]
[13]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
　MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(6):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[14]卢建林,侯建全,杨永青.125I-脱氧尿苷治疗膀胱癌的实验与临床研究[J].国际放射医学核医学杂志,2009,33(3):154.[doi:10.3760/cma.j.issn.1673-4114.2009.03.007]
　LU Jian-lin,HOU Jian-quan,YANG Yong-qin.Experimental and clinical treatment of bladder cancer with 125I-iododeoxyuridine[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(6):154.[doi:10.3760/cma.j.issn.1673-4114.2009.03.007]
[15]阎军艳,李险峰.放射治疗在晚期甲状腺乳头状癌中的研究进展[J].国际放射医学核医学杂志,2017,41(1):59.[doi:10.3760/cma.j.issn.1673-4114.2017.01.011]
　Yan Junyan,Li Xianfeng.Role of radiation therapy in the treatment of advanced papillary thyroid carcinoma and its research progress[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):59.[doi:10.3760/cma.j.issn.1673-4114.2017.01.011]
[16]张志祥,郑岚,罗加,等.131I治疗Graves病伴白细胞减少的临床研究[J].国际放射医学核医学杂志,2008,32(4):230.
　ZHANG Zhi-xiang,ZHENG Lan,LUO Jia,et al.Clinical study on 131I therapy Graves disease complicated with peripheral blood leukcytopenia[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(6):230.
[17]林琛,王鲁华,李俊雄,等.131Ⅰ治疗Graves’甲状腺亢进症伴白细胞减少前后血清和尿中β2-微球蛋白变化分析[J].国际放射医学核医学杂志,2007,31(2):98.
　LIN Chen,WANG Lu-hua,LI Jun-xiong,et al.Changes of serum and urine β2-microglobulin of leukopenia in hyperthyroidism of Graves’ disease before and after 131Ⅰ therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):98.
[18]崔丽群,张承刚,李玲玲.小剂量131I治疗青少年Graves’病85例患者疗效观察[J].国际放射医学核医学杂志,2007,31(4):226.
　CUI Li-qun,ZHANG Cheng-gang,LI Ling-ling.The observation of curative effects by therapy with low-dose 131I in younger with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):226.
[19]覃伟武.131Ⅰ治疗非Graves’甲状腺功能亢进及非毒性甲状腺肿后诱发Graves’病[J].国际放射医学核医学杂志,2006,30(6):325.
　QIN Wei-wu.Induction of Graves’ disease in patients with non-autoimmune hyperthyroidism or nontoxic goiter after radioiodine treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(6):325.
[20]秦岚,邵梦麟,王俊起.小剂量131I治疗甲亢的对比研究[J].国际放射医学核医学杂志,2005,29(3):112.
　QIN lan,SHAO Meng-lin,WANG Jun-qi.Comparative study of low dose 131I treatment in patients with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(6):112.

备注/Memo

备注/Memo:
收稿日期:2006-04-24。
通讯作者:李险峰,E-mail:Lixianfeng-lxf@263.net
更新日期/Last Update: 1900-01-01